Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses of Orelabrutinib in Mantle Cell Lymphoma

NCT05978739 is registered in ClinicalTrials.gov with InnoCare Pharma Inc. as lead sponsor.

NCT NCT05978739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05978739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses of Orelabrutinib in Mantle Cell Lymphoma
Lead sponsor
InnoCare Pharma Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 18, 2023
Completion date
December 10, 2024
Enrollment
40 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma